NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Legend Biotech Corp. LEGN
8 fiscal years on record · USD · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 1.0B
Revenue, FY2025 · full 8-year series below
Revenue $B
Net income $B
FY2025 · Revenue 1.0 · Net income -0.3
0.5B1.0B-0.2B-0.4B
2018202120242025
Compound annual growth
Revenue compounded at +68.8% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−29 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -13.3% · Net -28.8%
-200%-400%
201820212025
ROE
FY2025 · ROE -29.1%
-20%-40%-60%
201820212025
Three returns, three denominators.
Each USD of equity lost 29 cents this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 1.0 | 0.6 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Operating income $B | −0.1 | −0.3 | −0.5 | ◌ | ◌ | ◌ | ◌ | ◌ |
| EBITDA $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| Net income $B | −0.3 | −0.2 | −0.5 | −0.4 | −0.4 | −0.3 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | −0.2 | −0.4 | −0.2 | −0.2 | −0.2 | −0.1 | 0.3 |
| EPS, diluted $ | −0.81 | −0.48 | −1.47 | −1.40 | −1.43 | −1.13 | −0.51 | −0.01 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — |
| ROE % | −29.1 | −15.4 | −51.9 | −59.1 | −59.2 | −71.1 | −50.3 | −1.1 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED
Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 13 checks were skipped: cost of revenue is not tagged before 2020. 11 checks were skipped: EPS is not tagged before 2018.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2018